Healthcare & Pharma
The Healthcare & Pharma sector encompasses 15 tracked companies carrying $266.1B in combined long-term debt. Across the sector, $34.4B (7% of maturities) is due within the next 12 months. The majority of obligations ($318.6B) extend beyond five years, providing longer-term refinancing runway.
Companies in Sector
15
Total Sector Debt
$266.1B
High Risk
0
Avg Risk Score
2.8
| Company | Risk Score | Total Debt | 12mo Due |
|---|---|---|---|
|
Amgen
AMGN |
6/10 Medium Risk | $54.6B | $4.6B |
|
Bristol Myers Squibb
BMY |
5/10 Medium Risk | $44.8B | $2.0B |
|
AbbVie
ABBV |
4/10 Medium Risk | $64.5B | $6.0B |
|
Cvs Health
CVS |
4/10 Medium Risk | N/A | $4.0B |
|
Pfizer
PFE |
4/10 Medium Risk | N/A | $3.0B |
|
Gilead Sciences
GILD |
3/10 Low Risk | $24.9B | $2.8B |
|
Eli Lilly
LLY |
3/10 Low Risk | $29.5B | $781M |
|
Unitedhealth Group
UNH |
3/10 Low Risk | N/A | $6.1B |
|
Zoetis
ZTS |
3/10 Low Risk | N/A | $0 |
|
Cigna Group
CI |
2/10 Low Risk | N/A | $550M |
|
Biogen
BIIB |
1/10 Low Risk | $6.3B | $0 |
|
Johnson & Johnson
JNJ |
1/10 Low Risk | $41.4B | $2.0B |
|
Merck &
MRK |
1/10 Low Risk | N/A | $2.6B |
|
Regeneron Pharmaceuticals
REGN |
1/10 Low Risk | N/A | N/A |
|
Vertex Pharmaceuticals Inc / Ma
VRTX |
1/10 Low Risk | N/A | N/A |